Business
Statement re Press Comment
Statement re Press Comment.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 2494W Hemogenyx Pharmaceuticals PLC 13 November 2017 \n\nHemogenyx Pharmaceuticals Plc\n(\"Hemogenyx\" or the \"Company\")\n \nStatement re. media comment\n \nHemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, notes yesterday's article in the Mail on Sunday about the Company and a collaboration with the University of Oxford. \n \nA further announcement regarding this collaboration will be made in due course.\n \nEnquiries:\n \n\n\n\n\nHemogenyx Pharmaceuticals Limited\n\n\nwww.hemogenyx.com\n\n\n\n\nDr Vladislav Sandler, Chief Executive Officer & Co-Founder\n\n\nVia Walbrook PR\n\n\n\n\nDr Robin Campbell, Chairman\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOptiva Securities Ltd\n\n\nTel: +44 (0)20 3137 1902\n\n\n\n\nChristian Dennis \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nShard Capital Partners LLP\n\n\nTel: +44 (0)20 7186 9950\n\n\n\n\nDamon Heath, Erik Woolgar\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeterhouse Corporate Finance Limited\n\n\nTel: +44 (0)20 7469 0930\n\n\n\n\nLucy Williams/Duncan Vasey\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus\n\n\nMob: +44 (0)7980 541 893\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nAbout Hemogenyx Pharmaceuticals Plc\nHemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate...